Podcast Episodes
Back to Search
Episode 454: ESMO 2025 Prostate and Kidney Cancer Review
Silke, Tom and Brian discuss the prostate and RCC highlights from ESMO 2025
1 year ago
Episode 453: ESMO 2025 - IMvigor011
Alex Wyatt joins us to discuss Tom's IMvigor011 data and the field of ctDNA
1 year ago
Episode 452: ESMO 2025 - DV+ toripalimab in bladder cancer
Matt Galsky discusses the exciting Presidential session data from the Chinese phase 3 of DV+ toripalimab in advanced urothelial cancer.
1 year ago
Episode 451: ESMO 2025 - PSMAddition
Scott Tagawa discusses his ESMO Presidential presentation on Lu-PSMA-617 in patients with mHSPC
1 year ago
Episode 450: ESMO 2025 - CAPITELLO
Elena Castro describes the CAPITELLLO prostate cancer trial and her analysis from ESMO 2025
1 year ago
Episode 449: ESMO 2025 - ENZARAD
Paul Nguyen and Chris Sweeney double team the ENZARAD data and put it into context with other data including STAMPEDE
1 year ago
Episode 448: Neoadjuvant EV/Pembro in Cis-ineligible MIBC
Christof Vulsteke joins Brian and Tom to discuss his practice-changing data on neoadjuvant EVP in MIBC. More applause!!
1 year ago
Episode 447: ESMO 2025 - RAMPART
James Larkin joins to discuss adjuvant durva/treme vs observation in high risk resected RCC
1 year ago
Episode 446: ESMO 2025 - OPTIC and front-line RCC triplets
Cristina Rodriguez joins us to discuss her data on front-line triplets, and we also discuss the prospective RNAseq-based biomarker OPTIC study
1 year ago
Episode 445: ESMO 2025 - Systemic Checkpoint Inhibition plus BCG in NMIBC (POTOMAC and ALBAN)
Brad McGregor joins us on the heels of his #ESMO25 discussion of these important data in the NMIBC landscape.
1 year ago